5:22 PM
 | 
Oct 29, 2012
 |  BC Extra  |  Company News

Menarini, Oxford BioTherapeutics in cancer deal

Oxford BioTherapeutics Ltd. (Abingdon, U.K.) partnered with Menarini Group (Florence, Italy) to develop five of Oxford's antibody and antibody-drug conjugate (ADC) programs for undisclosed cancer indications. Oxford will provide undisclosed targets,...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >